Using 18F-FDG PET/CT to Diagnose and Treat Non-small Cell Lung Cancer

  • Liu Liu
  • Maomei Ruan
  • Wenhui Xie


Primary lung cancer is the leading cause of cancer-related death worldwide and is the most incident cancer, causing about 1.37 million deaths per year globally [1]. In China, both the incidence and the mortality rates of lung cancer also rank first, and the incidence of lung cancer is higher in males than in females, with a sex ratio (male/female) of 3–5:1. In recent years, the incidence of lung cancer in females has increased markedly; most of these patients are older than 40 years. In urban settings, both the incidence and mortality rates of lung cancer are slightly higher than in rural settings, whereas an opposite result was observed after age standardization. Most lung cancer is derived from the epithelium of the tunica mucosa bronchiorum. Lung cancer is classified as non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). NSCLC is the most common type, accounting for ~85% of lung cancers, including squamous carcinoma (SQCC), adenocarcinoma (ADC), and large cell carcinoma. The incidence of SCLC has been decreasing for decades [1].


  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedPubMedCentralGoogle Scholar
  2. 2.
    Kim SK, Allen-Auerbach M, Goldin J, Fueger BJ, Dahlbom M, Brown M, Czernin J, Schiepers C (2007) Accuracy of PET/CT in characterization of solitary pulmonary lesions. J Nucl Med 48:214–220PubMedGoogle Scholar
  3. 3.
    Herder GJ, Golding RP, Hoekstra OS, Comans EF, Teule GJ, Postmus PE, Smit EF (2004) The performance of( 18)F-fluorodeoxyglucose positron emission tomography in small solitary pulmonary nodules. Eur J Nucl Med Mol Imaging 31:1231–1236PubMedGoogle Scholar
  4. 4.
    Nomori H, Watanabe K, Ohtsuka T, Naruke T, Suemasu K, Uno K (2004) Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. Lung Cancer 45:19–27PubMedGoogle Scholar
  5. 5.
    Lin YY, Chen JH, Ding HJ, Liang JA, Yeh JJ, Kao CH (2012) Potential value of dual-time-point (1)(8)F-FDG PET compared with initial single-time-point imaging in differentiating malignant from benign pulmonary nodules: a systematic review and meta-analysis. Nucl Med Commun 33:1011–1018PubMedGoogle Scholar
  6. 6.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386PubMedGoogle Scholar
  7. 7.
    Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G (2004) The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 67:390–396PubMedGoogle Scholar
  8. 8.
    Ulas A, Bilici A, Durnali A, Tokluoglu S, Akinci S, Silay K, Oksuzoglu B, Alkis N (2016) Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases. Tumour Biol 37:1131–1140PubMedGoogle Scholar
  9. 9.
    Bae HM, Lee SH, Kim TM, Kim DW, Yang SC, Wu HG, Kim YW, Heo DS (2012) Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis. Lung Cancer 77:572–577PubMedGoogle Scholar
  10. 10.
    Nakamura H, Ando K, Shinmyo T, Morita K, Mochizuki A, Kurimoto N, Tatsunami S (2011) Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg 17:469–480PubMedGoogle Scholar
  11. 11.
    Schirrmeister H, Arslandemir C, Glatting G, Mayer-Steinacker R, Bommer M, Dreinhofer K, Buck A, Hetzel M (2004) Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 31:964–968PubMedGoogle Scholar
  12. 12.
    Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745–751PubMedGoogle Scholar
  13. 13.
    Hanibuchi M, Kim SJ, Fidler IJ, Nishioka Y (2014) The molecular biology of lung cancer brain metastasis: an overview of current comprehensions and future perspectives. J Med Invest 61:241–253PubMedGoogle Scholar
  14. 14.
    Dinnes J, Bancos I, Ferrante di Ruffano L, Chortis V, Davenport C, Bayliss S, Sahdev A, Guest P, Fassnacht M, Deeks JJ, Arlt W (2016) MANAGEMENT OF ENDOCRINE DISEASE: imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. Eur J Endocrinol 175:R51–R64PubMedPubMedCentralGoogle Scholar
  15. 15.
    Stenbygaard LE, Sorensen JB, Larsen H, Dombernowsky P (1999) Metastatic pattern in non-resectable non-small cell lung cancer. Acta Oncol 38:993–998PubMedGoogle Scholar
  16. 16.
    Kagohashi K, Satoh H, Ishikawa H, Ohtsuka M, Sekizawa K (2003) Liver metastasis at the time of initial diagnosis of lung cancer. Med Oncol 20:25–28PubMedGoogle Scholar
  17. 17.
    D’Souza MM, Sharma R, Mondal A, Jaimini A, Tripathi M, Saw SK, Singh D, Mishra A, Tripathi RP (2009) Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases. Nucl Med Commun 30:117–125PubMedGoogle Scholar
  18. 18.
    Erasmus JJ, McAdams HP, Rossi SE, Goodman PC, Coleman RE, Patz EF (2000) FDG PET of pleural effusions in patients with non-small cell lung cancer. AJR Am J Roentgenol 175:245–249PubMedGoogle Scholar
  19. 19.
    Schaffler GJ, Wolf G, Schoellnast H, Groell R, Maier A, Smolle-Juttner FM, Woltsche M, Fasching G, Nicoletti R, Aigner RM (2004) Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology 231:858–865PubMedGoogle Scholar
  20. 20.
    Herder GJ, Kramer H, Hoekstra OS, Smit EF, Pruim J, van Tinteren H, Comans EF, Verboom P, Uyl-de Groot CA, Welling A, Paul MA, Boers M, Postmus PE, Teule GJ, Groen HJ, POORT Study Group (2006) Traditional versus up-front [18F] fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol 24:1800–1806PubMedGoogle Scholar
  21. 21.
    Viney RC, Boyer MJ, King MT, Kenny PM, Pollicino CA, McLean JM, McCaughan BC, Fulham MJ (2004) Randomized controlled trial of the role of positron emission tomography in the management of stage I and II non-small-cell lung cancer. J Clin Oncol 22:2357–2362PubMedGoogle Scholar
  22. 22.
    Maziak DE, Darling GE, Inculet RI, Gulenchyn KY, Driedger AA, Ung YC, Miller JD, Gu CS, Cline KJ, Evans WK, Levine MN (2009) Positron emission tomography in staging early lung cancer: a randomized trial. Ann Intern Med 151:221–8, W-248PubMedGoogle Scholar
  23. 23.
    Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, Ravn J, Clementsen P, Hogholm A, Larsen K, Rasmussen T, Keiding S, Dirksen A, Gerke O, Skov B, Steffensen I, Hansen H, Vilmann P, Jacobsen G, Backer V, Maltbaek N, Pedersen J, Madsen H, Nielsen H, Hojgaard L (2009) Preoperative staging of lung cancer with combined PET-CT. N Engl J Med 361:32–39PubMedGoogle Scholar
  24. 24.
    MacManus MP, Hicks RJ, Matthews JP, Hogg A, McKenzie AF, Wirth A, Ware RE, Ball DL (2001) High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 50:287–293PubMedGoogle Scholar
  25. 25.
    Reed CE, Harpole DH, Posther KE, Woolson SL, Downey RJ, Meyers BF, Heelan RT, MacApinlac HA, Jung SH, Silvestri GA, Siegel BA, Rusch VW, American College of Surgeons Oncology Group Z0050 Trial (2003) Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 126:1943–1951PubMedGoogle Scholar
  26. 26.
    Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, von Schulthess GK, Steinert HC (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500–2507PubMedGoogle Scholar
  27. 27.
    Kozower BD, Meyers BF, Reed CE, Jones DR, Decker PA, Putnam JB Jr (2008) Does positron emission tomography prevent nontherapeutic pulmonary resections for clinical stage IA lung cancer? Ann Thorac Surg 85:1166–1169; discussion 1169–1170.PubMedGoogle Scholar
  28. 28.
    De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J, Verschakelen JA (2007) Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 17:23–32PubMedGoogle Scholar
  29. 29.
    Carnio S, Novello S, Papotti M, Loiacono M, Scagliotti GV (2013) Prognostic and predictive biomarkers in early stage non-small cell lung cancer: tumor based approaches including gene signatures. Transl Lung Cancer Res 2:372–381PubMedPubMedCentralGoogle Scholar
  30. 30.
    Jimenez-Bonilla JF, Quirce R, Martinez-Rodriguez I, Banzo I, Rubio-Vassallo AS, Del Castillo-Matos R, Ortega-Nava F, Martinez-Amador N, Ibanez-Bravo S, Carril JM (2013) Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT. Lung Cancer 81:71–76PubMedGoogle Scholar
  31. 31.
    Liu J, Dong M, Sun X, Li W, Xing L, Yu J (2016) Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis. PLoS One 11:e0146195PubMedPubMedCentralGoogle Scholar
  32. 32.
    Ito R, Iwano S, Kishimoto M, Ito S, Kato K, Naganawa S (2015) Correlation between FDG-PET/CT findings and solid type non-small cell cancer prognostic factors: are there differences between adenocarcinoma and squamous cell carcinoma? Ann Nucl Med 29:897–905PubMedGoogle Scholar
  33. 33.
    Chaft JE, Dunphy M, Naidoo J, Travis WD, Hellmann M, Woo K, Downey R, Rusch V, Ginsberg MS, Azzoli CG, Kris MG (2016) Adaptive neoadjuvant chemotherapy guided by (18)F-FDG PET in resectable non-small cell lung cancers: the NEOSCAN trial. J Thorac Oncol 11:537–544PubMedGoogle Scholar
  34. 34.
    Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, Lutolf UM, Steinert HC, Von Schulthess GK (2003) Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57:853–863PubMedGoogle Scholar
  35. 35.
    Erdi YE, Rosenzweig K, Erdi AK, Macapinlac HA, Hu YC, Braban LE, Humm JL, Squire OD, Chui CS, Larson SM, Yorke ED (2002) Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 62:51–60PubMedGoogle Scholar
  36. 36.
    Hellwig D, Baum RP, Kirsch C (2009) FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin 48:59–69, quiz N58–59.PubMedGoogle Scholar
  37. 37.
    De Wever W, Stroobants S, Coolen J, Verschakelen JA (2009) Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J 33:201–212PubMedGoogle Scholar
  38. 38.
    Rosenzweig KE, Sura S, Jackson A, Yorke E (2007) Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol 25:5557–5561PubMedGoogle Scholar
  39. 39.
    Grills IS, Hope AJ, Guckenberger M, Kestin LL, Werner-Wasik M, Yan D, Sonke JJ, Bissonnette JP, Wilbert J, Xiao Y, Belderbos J (2012) A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol 7:1382–1393PubMedGoogle Scholar
  40. 40.
    Aerts HJ, van Baardwijk AA, Petit SF, Offermann C, Loon J, Houben R, Dingemans AM, Wanders R, Boersma L, Borger J, Bootsma G, Geraedts W, Pitz C, Simons J, Wouters BG, Oellers M, Lambin P, Bosmans G, Dekker AL, De Ruysscher D (2009) Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 91:386–392PubMedPubMedCentralGoogle Scholar
  41. 41.
    Larici AR, del Ciello A, Maggi F, Santoro SI, Meduri B, Valentini V, Giordano A, Bonomo L (2011) Lung abnormalities at multimodality imaging after radiation therapy for non-small cell lung cancer. Radiographics 31:771–789PubMedGoogle Scholar
  42. 42.
    William WN Jr, Pataer A, Kalhor N, Correa AM, Rice DC, Wistuba II, Heymach J, Lee JJ, Kim ES, Munden R, Gold KA, Papadimitrakopoulou V, Swisher SG, Erasmus JJ, University of Texas M.D. Anderson Lung Cancer Collaborative Research Group (2013) Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol 8:222–228PubMedPubMedCentralGoogle Scholar
  43. 43.
    van Loon J, Grutters JP, Wanders R, Boersma L, Dingemans AM, Bootsma G, Geraedts W, Pitz C, Simons J, Brans B, Snoep G, Hochstenbag M, Lambin P, De Ruysscher D (2010) 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation. Eur J Cancer 46:110–119PubMedGoogle Scholar
  44. 44.
    de Cabanyes Candela S, Detterbeck FC (2010) A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. J Thorac Oncol 5:389–398PubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. and Shanghai Jiao Tong University Press 2019

Authors and Affiliations

  • Liu Liu
    • 1
  • Maomei Ruan
    • 1
  • Wenhui Xie
    • 1
  1. 1.Department of Nuclear MedicineShanghai Chest HospitalShanghaiP. R. China

Personalised recommendations